Mesoblast Allogeneic Cell Therapy Products Are Designated U.S. Country of Origin and Not Subject to U.S. Tariffs
April 03, 2025 18:58 ET | Source: Mesoblast Limited NEW YORK, April…
Mesoblast Added to S&P/ASX 200 INDEX
March 06, 2025 18:54 ET | Source: Mesoblast Limited NEW YORK, March…
Mesoblasts RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
December 18, 2024 19:08 ET | Source: Mesoblast Limited RYONCIL (remestemcel-L) is…
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Phase 3 trial results published in European Journal of Heart Failure identify…